Neurogene full yr net loss widens on higher R&D costs

Neurogene

24/03/2026 11:39

Overview

US biotech reported full yr net loss widened, driven by higher Rett syndrome trial costs

Company ended yr with $269 mln in cash and investments, funding runway through Q1 2028

NGN-401 gene therapy program achieved full enrollment in Embolden trial, received FDA Breakthrough designation

Outlook

Company expects to complete dosing in Embolden trial in Q2 2026

Neurogene plans to present updated interim safety and efficacy data mid-2026

Company to initiate Process Performance Qualification campaign in mid-2026

Result Drivers

RETT SYNDROME TRIAL COSTS - Higher R&D expenses were mainly due to increased clinical trial costs and employee-related expenses for the Rett syndrome program

HIGHER G&A EXPENSES - General and administrative costs rose due to increased non-cash stock-based compensation and headcount

Company press release: ID:nBwbLNyhSa

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
FY Net Income
-$90.35 mln
FY Operating Expenses
$103.33 mln
FY Operating Income
-$103.33 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Neurogene Inc is $60.00, about 209.9% above its March 23 closing price of $19.36

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)